|
|
Upfront Briefing
HIV prevention just became a billion-dollar-a-quarter, KKR decided the least glamorous corner of medtech was worth $5.7B, and Merck is still buying extra innings around Keytruda. Translation: commercial beats matter, sponsors are paying up for the plumbing, and combo strategy remains oncology’s favorite sequel. Elsewhere, earnings season is doing the heavy lifting — and with Lilly’s print landing this morning, the obesity scoreboard gets its other half before lunch.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,736.5 |
1.8% |
12.8% |
| Nasdaq 100 |
29,733.2 |
3.3% |
18.0% |
| Russell 2000 |
3,037.0 |
1.9% |
21.1% |
| Healthcare (XLV) |
162.1 |
(0.1%) |
4.2% |
| Biotech (XBI) |
151.9 |
3.1% |
25.0% |
| Nasdaq Biotech (NBI) |
6,578.5 |
2.3% |
15.3% |
| Clinical Trials (BBC) |
51.1 |
4.3% |
35.7% |
|
- Biotech outran large-cap pharma on a heavy earnings tape: Gilead’s PrEP franchise cleared $1B in a quarter for the first time and Amgen posted 10% revenue growth, carrying XBI 3.1% higher, while XLV was pinned by Novo Nordisk’s 6% slide on a Wegovy pill miss.
- The broad tape closed at records on optimism over reopening the Strait of Hormuz and a blowout Palantir print (+29%), which dragged the AI complex up with it — the Nasdaq 100 added 3.3% and the S&P 500 1.8% for its first record close since early June, with Kevin Warsh’s opening weeks at the Fed keeping rate-cut bets capped.
- Market data: U.S. cash close Tuesday, 4 August 2026.
The Big 3
|
1
|
Gilead PrEP tops $1B as Yeztugo beats forecasts
|
- Yeztugo booked $232 million in Q2 against $221 million consensus, and Gilead’s HIV PrEP franchise cleared $1 billion in a quarter for the first time, doubling year over year.
- Why it matters: A $1B quarter puts PrEP on a roughly $4B annual run rate and turns Yeztugo from a launch story into a franchise — Gilead lifted full-year HIV growth guidance to 9–10% from 8% on the back of it, against a US PrEP market growing 14%. The near-term catalyst is the 27 August PDUFA on bictegravir/lenacapavir, with a once-weekly oral lenacapavir sNDA already accepted for 2 February 2027. That cadence squeezes ViiV’s Apretude on the prevention side and builds a defensible answer to the eventual Biktarvy patent cliff. Access pricing through PEPFAR and the Global Fund caps the ex-US contribution, and the stock eased after hours on an otherwise clean print.
- Source: Endpoints
- More: Gilead IR
|
|
2
|
KKR takes Integer private in $5.7B all-cash deal
|
- KKR will pay $127 per share in cash for medtech CDMO Integer Holdings (NYSE: ITGR), an enterprise value of roughly $5.7 billion including assumed debt, with close targeted by year-end.
- Why it matters: $127 a share against $1.85 billion of 2025 sales growing 8% puts KKR at roughly 3x revenue for the plumbing behind cardiovascular and neuromodulation devices. Integer closed at $124.50 on the announcement, a 2% discount to terms — the tape is pricing completion as near-certain rather than betting on a bump. This is the third sizeable sponsor take-private in healthcare in quick succession, after Blackstone and TPG’s Hologic deal at up to $18.3 billion and American Industrial Partners’ $1.27 billion for Avanos. Private equity is re-rating device manufacturing capacity while strategics keep capital pointed at drug pipelines. The open risk is regulatory review; Goldman ran the sell side against a four-bank buyer syndicate.
- Source: Fierce Biotech
- More: Integer IR
|
| 3 | Merck doubles down on sac-TMT as TL1A splits 1–1 |
- Alongside Q2 results, Merck said it will run a lung cancer trial of TROP2 ADC sacituzumab tirumotecan plus Keytruda, and reported that tulisokibart missed its primary endpoint in Phase 2 systemic sclerosis-associated ILD while hitting primary and key secondary endpoints in Phase 2b hidradenitis suppurativa.
- Why it matters: Both legs point at the same 2028 problem — Keytruda’s US patent expiry. The sac-TMT study follows OptiTROP-Lung05, where the ADC plus Keytruda cut progression risk 65% with a 70.2% ORR against 42% for Keytruda alone, though that trial ran in China without a Keytruda-chemo control, so the global study is what decides whether the ADC displaces platinum in first line. The diversification leg is patchier: Phase 3 in ulcerative colitis and now Phase 2b in HS keep tulisokibart on track as a product, but the SSc-ILD miss undercuts Dean Li’s case for TL1A as an immunofibrosis node the way TNF and IL-23 became nodes. Squeezed on both fronts by Akeso and Summit’s ivonescimab in NSCLC and Roche’s afimkibart on TL1A, with Kelun-Biotech carrying China-sourcing overhang.
- Source: Endpoints
- More: Fierce Biotech; BioPharma Dive
|
Everything Else that broke
- Hinge Health (NYSE: HNGE) agreed to acquire Cylinder Health for $105M in cash, entering GI care alongside Q2 revenue of $213M (+53%) and full-year guidance raised to $856–860M. — Endpoints
- Novo Nordisk fell 6% despite raising full-year guidance to 0% to (6%), as a 2% Wegovy pill miss on destocking and a CagriSema setback overshadowed a top- and bottom-line beat. — BioSpace
- Amgen posted Q2 revenue up 10% to $10.1B with its six growth drivers up 26%, and discontinued Phase 1 obesity candidate AMG 513, concentrating its weight-loss case on Phase 3 MariTide. — Fierce Biotech
- Pfizer cut two clinical-stage obesity programs in its quarterly pipeline clearout — a GLP-1 receptor agonist inherited from the Metsera buyout and a GIPR antagonist. — Fierce Biotech
- Pfizer’s CEO defended a $7B bolt-on M&A strategy as peers accelerate dealmaking. — BioSpace
- Lisata Therapeutics cut 72% of staff including its chief medical officer after its planned merger with Kuva Labs collapsed, and is suing Kuva over the failed deal. — Fierce Biotech
- Smith & Nephew cut its 2026 sales outlook as weakness in US knee implants and wound care outweighed sports medicine growth. — Fierce Biotech
- Basilea secured another $5.4M from BARDA for ceftibuten-ledaborbactam development. — PR
- Spyre flagged positive Phase 2 SKYLINE induction topline data for SPY001 and SPY002. — PR
- Pacira posted $192.4M in Q2 revenue, up 6% year over year. — PR
- Syndax reported $73M in Q2 revenue, up 92% year over year. — PR
- Cumberland reported after closing a $100M strategic transaction and funding a special dividend. — PR
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Hinge Health agreed to buy Cylinder Health for $105M in cash to enter digestive care. — Endpoints
- KKR / Integer Holdings — $127 per share all-cash take-private at approximately $5.7B enterprise value including assumed debt; Goldman Sachs advised Integer, with Centerview, Barclays, Citi and Raymond James advising KKR. Close expected by year-end (see The Big 3). — Fierce Biotech
- Supernus Pharmaceuticals / Indivior — all-stock merger of equals at 1.5401 INDV shares per SUPN share, creating a $2.2B-revenue CNS company with $888M pro forma adjusted EBITDA and $125M in expected annual synergies; Indivior funds a $1B pre-closing special dividend partly via a $650M Citibank term loan. Trades as SUPN on Nasdaq, targeted to close Q4 2026. — GlobeNewswire
- IQVIA and Medera formed a cardiac gene therapy collaboration spanning development and human-based discovery. — PR
VC / Private Financings
- No notable VC / private financings in the last 24 hours. — BioBucks
IPOs / Follow-Ons
- Latigo Biotherapeutics set terms for a $247M IPO to fund its clinical-stage non-opioid pain pipeline, positioned against Vertex’s Journavx. — Fierce Biotech
- Grace Therapeutics priced a $10M private placement expected to fund operations through calendar 2028. — PR
Academic Corner - Designing small-molecule binding proteins. — Nature RDD
- Optimizing translation of therapeutic mRNAs. — Nature RDD
|
A shot that needs a calendar reminder twice a year, and a buyout that needed four banks.
— BioBucks Team
|
|
|
